BactiQuant (BACTIQ) Q4 2024 TU earnings summary

Executive summary

• Q4 2024 saw strong order intake, especially in November and December, with several million-krone orders for online robot samplers in the Pharma and Water Utility segments, though these had limited impact on 2024 revenue due to late timing.

• The year was characterized by large pilot projects and delayed major orders, setting the stage for significant revenue growth in 2025.

Financial highlights

• 2024 revenue reached 7.3 million DKK, in line with guidance of 6–8 million DKK.

• Recurring revenue was stable at 4.5 million DKK, unchanged from 2023.

• Hardware sales (BactiQuant Online and Mobile Lab) declined from 6.8 million DKK in 2023 to 2.1 million DKK in 2024.

• Other revenue (installation, training, etc.) fell from 1.0 million DKK in 2023 to 0.7 million DKK in 2024.

Outlook and guidance

• 2025 revenue is expected in the range of 10–14 million DKK.

• EBITDA for 2025 is forecasted between -8 and -11 million DKK.

• Strong order backlog and pipeline support expectations for marked revenue growth in 2025.